Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
about
Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumorsNew therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.Dosimetry for radiopharmaceutical therapy(68)Ga-labeled radiopharmaceuticals for positron emission tomography.Study of the impact of tissue density heterogeneities on 3-dimensional abdominal dosimetry: comparison between dose kernel convolution and direct Monte Carlo methods.In vivo molecular targeted radiotherapy.Can DCE-MRI explain the heterogeneity in radiopeptide uptake imaged by SPECT in a pancreatic neuroendocrine tumor model?Effects of chelator modifications on (68)Ga-labeled [Tyr (3)]octreotide conjugates.Nonsurgical Strategies in Patients With NET Liver Metastases: A Protocol of Four Systematic Reviews.Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?Institutional guidelines and ongoing studies in management of liver tumours: the experience of the European Institute of Oncology.A multimodal approach to the management of neuroendocrine tumour liver metastasesClinical radionuclide therapy dosimetry: the quest for the "Holy Gray".Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide.Stroma targeting nuclear imaging and radiopharmaceuticals.Requirements regarding dose rate and exposure time for killing of tumour cells in beta particle radionuclide therapy.Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma.Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy.PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues.The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursPeptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicityEvaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody moleculesBiology and treatment of metastatic gastrointestinal neuroendocrine tumors.Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptorsNephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy.Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis.Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate.Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma.Effects of therapy with [177Lu-DOTA 0,Tyr 3]octreotate on endocrine function.Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrA Modular Dual Labeling Scaffold That Retains Agonistic Properties for Somatostatin Receptor Targeting.Selective internal radiation therapy for gastrointestinal neuroendocrine tumour liver metastases: a new and effective modality for treatment.Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting.Neuroendocrine tumors: a focus on liver metastatic lesions.The 68Ge/ 68Ga generator has high potential, but when can we use 68Ga-labelled tracers in clinical routine?GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETs) - APPROACH TO DIAGNOSIS AND MANAGEMENT.Software-assisted dosimetry in peptide receptor radionuclide therapy with 177Lutetium-DOTATATE for various imaging scenarios.Update on radionuclide therapy in oncology.The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuroendocrine tumors.
P2860
Q28290833-0DA2ADF4-9267-4ADE-BE17-502D54E7F95CQ30364864-CA657163-AD95-49D5-9E81-ABDB39D7B6BBQ33665116-995771EE-DC6D-4A02-BE41-C7631E23417CQ33704038-9ADA4A76-A326-4CA3-ADFA-6DD2373D4C1FQ33768719-F63DD6D3-7265-470D-84C8-448487E9EA5CQ34991297-D47AE01E-6E5E-41C8-BDA2-4A1F8FAA0CD3Q35015049-7A9FF195-BABA-43FC-BE40-82DED5BE094FQ35087810-1FA93C79-C9EF-448C-845A-C27FAC47CC35Q35115068-8D1F88D5-9AF7-44E0-9F7B-BF0AD3919BD2Q35201583-16772A77-568C-4F81-BB65-F68E85DA9DEFQ35602256-5811F47F-A07C-4915-9B60-87171D702E5EQ35810562-FF5ADA88-31F4-4EAB-AA30-9B9F6BC36338Q35880923-9774BF16-3C60-46FF-AC86-934750074EE2Q35999552-491957F3-1D0D-4529-A918-A99DE4214657Q35999606-78D76CAE-FEA1-43AD-AFCE-6CCF93FF6DFBQ36021361-DE9950D0-00B2-4B36-AB52-2ABDF4A4B932Q36125143-0FA96F4A-8813-45AF-80B8-F9F9D0EA6B11Q36300599-7D55F7F6-A7F1-4596-9DEF-D48B2D16A934Q36338484-E80A4DA5-2D81-448B-B2D0-593FA46A208FQ36755905-9DC37239-225F-4BB7-9D2B-8161BCAB8385Q36775316-41CC397E-77CE-4E48-AA96-E67D2674FDEBQ36922818-D588F8E4-D309-43E0-9ED1-9524CF442B0FQ37077832-5D1ABE4E-0945-4B82-8791-5422E213AA2DQ37085052-E6172004-6D28-4268-B767-65820B601CC3Q37122608-C3B51386-E1F0-4668-91B8-B291BFAA3287Q37167160-BFDF0A86-6058-49B0-B135-9BE2DA311951Q37201458-F0A58F18-4C6E-4A79-B9C3-21DED691B461Q37214696-91658038-B360-4DB0-8CBA-08A48A117028Q37258209-93D039B0-6D03-4373-BF7D-B05ABC554F21Q37392534-F9AC472E-4ABC-46D0-9FF5-111915AAFC2DQ37425156-6D44D22E-2C17-4B5A-8B9B-AE671E47454DQ38749965-64A6614F-E346-445D-9251-F1F5F6590537Q39491049-77D680FA-BE36-43D7-9365-B8100AEA78C4Q39973557-5DA3BAD5-24EB-4820-880F-AA548180E042Q42175071-C83B2352-15AB-4BB9-BCFD-C0803394D917Q42594589-0BA471E0-6366-48A9-866E-2419764D3C65Q42748870-C5859A58-0211-49A9-9DA8-898F6D5C9F60Q47163935-EA1DBB6D-9886-474A-B471-995CAFBDD59FQ47552162-548EB44B-3FBD-4C0E-9E9F-A7F1BDE1303DQ47589004-4BCC3519-CA47-43D8-BA3D-9D9F1216E1FC
P2860
Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Overview of results of peptide ...... olabeled somatostatin analogs.
@ast
Overview of results of peptide ...... olabeled somatostatin analogs.
@en
type
label
Overview of results of peptide ...... olabeled somatostatin analogs.
@ast
Overview of results of peptide ...... olabeled somatostatin analogs.
@en
prefLabel
Overview of results of peptide ...... olabeled somatostatin analogs.
@ast
Overview of results of peptide ...... olabeled somatostatin analogs.
@en
P2093
P1476
Overview of results of peptide ...... iolabeled somatostatin analogs
@en
P2093
Dik J Kwekkeboom
Eric P Krenning
Giovanni Paganelli
Helmut R Maecke
Jan Mueller-Brand
Larry K Kvols
Lisa Bodei
Lowell B Anthony
Marco Chinol
Roelf Valkema
P304
P407
P478
46 Suppl 1
P577
2005-01-01T00:00:00Z